Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.
The purpose of this study is to assess the antibody response to COVID-19 vaccination in a cohort of patients with sickle cell disease (SCD) and to assess vaccine and SCD related complications around the time of vaccination.
The purpose of this study is to evaluate the efficacy, safety and tolerability of treatment with EDIT-301 in adult subjects with severe sickle cell disease (SCD).
12 United States sites
2 Canada sites
18 Years to 50 Years Years
Phase 1/Phase 2
The overall purpose of this proposed study is to improve management of vaso-occlusive episodes (VOEs) in adult EDs.
8 United States sites
18 Years to 45 Years Years
2
Not Applicable
This is a phase 1, first-in-human, multi-center, open-label, single dose cohort study to evaluate the safety and tolerability, pharmacokinetics (PK), exploratory pharmacodynamics (PD), and biomarkers of target engagement of CSL889 following single intravenous (IV) doses in subjects with sickle cell disease (SCD).
4 United States sites
4 United Kingdom sites
1 Netherlands site
18 Years to 60 Years Years
Phase 1
The overall purpose of this proposed study is to improve management of vaso-occlusive episodes (VOEs) in adult EDs.
8 United States sites
18 Years to 45 Years Years
2
Not Applicable
This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).
42 United States sites
4 France sites
4 Spain sites
2 Canada sites
2 Germany sites
2 Italy sites
1 United Kingdom site
12 Years to 65 Years Years
Phase 2/Phase 3
This study is a Phase 3, randomized, double-blind, placebo-controlled study of voxelotor in pediatric participants, aged ≥ 2 to < 15 years old, with Sickle Cell Disease.
17 United States sites
5 Nigeria sites
4 Egypt sites
4 United Kingdom sites
3 Italy sites
3 Kenya sites
2 Ghana sites
2 Oman sites
2 Saudi Arabia sites
1 France site
2 Years to 14 Years Years
Phase 3
SHP655 is a medicine used to treat sickle cell disease (SCD).
This study aims to enroll 58 pre-adolescent (<13 years) pediatric participants with sickle cell disease (SCD) who have a pre-adolescent sibling bone marrow donor.
The STRIDE Biorepository is an optional substudy available to participants in "Bone Marrow Transplantation vs Standard of Care in Patients with Severe Sickle Cell Disease (BMT CTN 1503) (STRIDE)".